A RETROSPECTIVE STUDY OF TREATMENT OUTCOMES IN PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER HEMATOPOIETIC CELL TRANSPLANT OR SOLID ORGAN TRANSPLANT WHO HAVE FAILED RITUXIMAB OR RITUXIMAB PLUS CHEMOTHERAPY.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
ATARA BIOTHERAPEUTICS, INC.
RJM GROUP LLC
Cita
A RETROSPECTIVE STUDY OF TREATMENT OUTCOMES IN PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER HEMATOPOIETIC CELL TRANSPLANT OR SOLID ORGAN TRANSPLANT WHO HAVE FAILED RITUXIMAB OR RITUXIMAB PLUS CHEMOTHERAPY. (ABI-RIT-2018-01). ATARA BIOTHERAPEUTICS, INC.; RJM GROUP LLC. 2020-2020. IP:JAIME SANZ CABALLER.
Portal de investigación